Are side effects of xtandi worse than darolutamide

Comparing Xtandi vs Darolutamide Side Effects

Great question—this is something many patients with prostate cancer consider when discussing treatment options with their oncologist. Let me break down what we know about these two medications.

What These Drugs Are

Both Xtandi (enzalutamide) and darolutamide are androgen receptor inhibitors—they work by blocking male hormones that fuel prostate cancer growth. They're used for castration-resistant prostate cancer (CRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).

Side Effect Profiles: What the Data Shows

XTANDI (Enzalutamide) commonly reported side effects:

• Fatigue (30-40% of patients)
• Hot flashes (20-30%)
• Diarrhea (20-25%)
• Hypertension/high blood pressure (15-20%)
• Seizures (rare, <1%, but important to monitor)
• Cognitive effects ("chemo brain")

DAROLUTAMIDE commonly reported side effects:

• Fatigue (20-25%)
• Hot flashes (15-20%)
• Diarrhea (15-18%)
• Rash (10-15%)
• Generally considered to have a slightly milder side effect profile

The Clinical Reality

According to NCCN Guidelines for Prostate Cancer, both drugs are considered standard options, and the choice often depends on:

• Your individual tolerance and medical history
• Other medications you're taking
• Specific side effects that concern you most
• Your PSA response and disease progression

Key point: Studies like the ARAMIS trial (darolutamide) and AFFIRM trial (enzalutamide) show both are effective, but individual responses vary significantly. What causes severe side effects in one patient may be minimal in another.

Questions to Ask Your Oncologist

1. "Based on my specific health situation, which drug do you recommend and why?"
2. "What side effects should I watch for, and when should I contact you?"
3. "Are there any drug interactions with my current medications?"
4. "If I experience significant side effects, can we switch to the other medication?"
5. "How will we monitor my response to treatment?"

Important Context

The "better" drug isn't about which has fewer side effects overall—it's about which is better for your specific case. Your oncologist will consider your PSA levels, metastatic disease pattern, kidney/liver function, and other factors when recommending one over the other.

According to the American Cancer Society, both medications have demonstrated survival benefits in advanced prostate cancer, so either could be appropriate depending on your individual circumstances.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.